chevrons

Back to Previous Page

Company Quarterly Earnings Update – MCH VN – 2019 Q3

Summary of the 9M/2019 results of Masan Consumer Corp. (MCH VN) 

9M/2019 results: highlights
  • Revenue increased by 5.7% y/y. Among business lines, seasoning stagnated, whereas convenience foods grew by 5% y/y. Non-alcoholic beverages however was the major growth driver with an expansion of 29.0% y/y, contributing 20% to MCH’s total revenue. The coffee business struggled among increased competition. Its sales fell by 16.4% y/y. The processed meat segment thrived as a result of the partnership with Jin-Ju. Its sale doubled in the 9M 2019.
  • In 9M 2019, the company’s overall gross margin fell to 42.1% as the less profitable beverage products contributed more to the company’s total sales. However, MCH optimized its OPEX. As a result, it managed to keep its bottom line stable.
  • By the end of Q3/2019, MCH’s financial position stayed solid. Cash equivalents accounted for 11.1% of total assets. Meanwhile, the company’s leverage remained moderate with a D/E and a D/A of 0.43x and of 0.24x respectively. However, we are still concerned with MCH’s outstanding loans/receivables to its parent company (MSN), which amounted to VND9,700bn (50% of total assets)
Outlook
  • As for 2019, we estimate revenue of VND18,202bn, +7.0% y/y, and net profit of VND3,549bn, +5.4% y/y.
  • From 2020 until 2023, we forecast MCH’s revenue to rise by a CAGR of 6.8%. It will continue its premiumization strategy for both the seasoning and the convenience foods segment. But the results are likely to be different: We forecast the two to grow by a CAGR of 7.6% and of 0.6% respectively. For the non-alcoholic beverages segment, we estimate a CAGR of 7.7% as the low base effect is likely to abate.  We expect the coffee business to stagnate as the result of increasing competition. As for the processed meat segment, the partnership with Jin-Ju should continue to bear fruit, and we forecast a CAGR of 16.1% between 2020-2023.
  • We forecast MCH’s bottom line to increase by a CAGR of 8.4% between 2020-2023. The company is likely to be able to control its operation expenses at ~23.0% of total sales, and, as a result, it should maintain a net margin at 20.0%
Recommendation

Company ratings and target prices are accessible for clients only.

If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.

Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.


Featured image credit: masangroup.com

Related News & Insights
Find out more navigation_button
news

Summary of 9M 2025 results and outlook of Nam Long Investment (NLG VN) The real estate market saw a rebound in new supply, supported by government initiatives that accelerated project development and sales launches. However, this recovery remains insufficient to narrow the supply-demand gap, as new launches are still concentrated in high-end and luxury segments. […]

Read Newsarrow
news

Summary of 9M 2025 results and outlook of Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD VN) Net revenue rose 8.5% y/y to VND1,355bn, driven by self-produced product sales, which accounted for 98.1% of total revenue. In Hospital channel: Revenue increased by 11.7% y/y to VND891bn, led by strong sales of key products including oncology […]

Read Newsarrow
news

Summary of 9M 2025 results and outlook of Hau Giang Pharmaceutical JSC (DHG VN) Net revenue grew 7.0% to VND3,524bn. In pharmacy channel (84.9% of total sales), early in the year, new tax and invoicing regulations posed challenges for traditional pharmacies, DHG’s main clients. It swiftly implemented support programs—including e-invoicing software assistance, promotional initiatives, and […]

Read Newsarrow
Find out more navigation_button